Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
HCXT-2001 in Psoriasis: NCT07792928 Clinical Landscape Report 2026
11 September 2026
NCT07792928 clinical landscape for Psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
9 min read
Lenvatinib mesylate in Locally Advanced Clear Cell Renal Cell Carcinoma: NCT07741617 Clinical Landscape Report 2026
11 September 2026
NCT07741617 clinical landscape for Locally Advanced Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develo…
Read →
9 min read
Zoldonrasib in Pancreatic adenocarcinoma metastatic: NCT07805954 Clinical Landscape Report 2026
11 September 2026
NCT07805954 clinical landscape for Pancreatic adenocarcinoma metastatic: endpoints, sponsor, phase, geography, readouts, asset context and development white…
Read →
9 min read
Risvutatug Rezetecan in Metastatic castration-resistant prostate cancer: NCT07802704 Clinical Landscape Report 2026
11 September 2026
NCT07802704 clinical landscape for Metastatic castration-resistant prostate cancer: endpoints, sponsor, phase, geography, readouts, asset context and develop…
Read →
9 min read
ABBV-253 in Ovarian Cancer: NCT07807956 Clinical Landscape Report 2026
11 September 2026
NCT07807956 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
9 min read
Anlotinib Dihydrochloride in EGFR-mutated non-small Cell Lung Cancer: NCT07807722 Clinical Landscape Report 2026
11 September 2026
NCT07807722 clinical landscape for EGFR-mutated non-small Cell Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
Read →
9 min read
IBI3046 in Obesity: NCT07809945 Clinical Landscape Report 2026
11 September 2026
NCT07809945 clinical landscape for Obesity: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
9 min read
Ublituximab in Myasthenia Gravis: NCT07673744 Clinical Landscape Report 2026
11 September 2026
NCT07673744 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
9 min read
VV169 in Relapse multiple myeloma: NCT07802717 Clinical Landscape Report 2026
11 September 2026
NCT07802717 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
9 min read
Efimosfermin alfa in Metabolic Dysfunction Associated Steatohepatitis: NCT07701993 Clinical Landscape Report 2026
11 September 2026
NCT07701993 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
Read →
9 min read
Indapamide in Multiple Sclerosis, Secondary Progressive: NCT07765212 Clinical Landscape Report 2026
11 September 2026
NCT07765212 clinical landscape for Multiple Sclerosis, Secondary Progressive: endpoints, sponsor, phase, geography, readouts, asset context and development w…
Read →
9 min read
Temozolomide in Glioblastoma Multiforme: NCT07754734 Clinical Landscape Report 2026
11 September 2026
NCT07754734 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
<
1
<<
328
329
330
331
332
>>
2260
>